Retatrutide, also called LY3437943, is a triple GIP, GLP-1, and glucagon receptor agonist studied for obesity, type 2 diabetes, and metabolic liver disease. Human randomized trials report effects on weight, glycemic measures, body composition, appetite, and liver-fat outcomes, but patient use should be discussed with a licensed clinician 1, 2, 3.
Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →What it is
Retatrutide is the generic INN name for LY3437943, a medicine studied as a triple agonist at the GIP, GLP-1, and glucagon receptors. The provided evidence does not supply a brand name for retatrutide.
In plain English, retatrutide is part of the broader incretin and GLP-1-based medicine family, but it is not the same receptor design as semaglutide or tirzepatide. Human trials describe it as a GIP, GLP-1, and glucagon receptor agonist in people with obesity and in people with type 2 diabetes 1, 2.
The main conditions studied in the retrieved human literature are obesity or overweight, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, body composition, appetite and eating behavior, and lipid-related biomarkers such as ANGPTL3/8 1, 2, 3, 5, 7, 8.
Names, class, and how it differs from single-receptor GLP-1 medicines
| Name or term | What it means |
|---|---|
| Retatrutide | Generic INN name used in the provided clinical literature. |
| LY3437943 | Research identifier used in early human trials 6. |
| Drug class | Incretin-based triple agonist with GIP, GLP-1, and glucagon receptor activity 2. |
| Brand name | No brand name was supplied in the provided evidence. |
| Single-receptor GLP-1 medicines | Medicines such as semaglutide act through GLP-1 receptor biology; retatrutide is described in trials as acting at three receptors, not one 1, 2. |
Mechanism of action
Retatrutide acts at 3 hormone receptors in the retrieved human trials: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. Those receptor targets are demonstrated by how the drug is described and tested in human randomized studies 1, 2, 6.
GIP receptor activity
GIP stands for glucose-dependent insulinotropic polypeptide. Retatrutide’s GIP receptor activity is part of why it is grouped with newer incretin polyagonists rather than older single-receptor GLP-1 medicines 2.
GLP-1 receptor activity
GLP-1 stands for glucagon-like peptide-1. Retatrutide’s GLP-1 receptor activity connects it to the broader GLP-1 medication category studied for obesity, overweight, and type 2 diabetes outcomes 1, 2, 9.
Glucagon receptor activity
Glucagon receptor activity is the third part of the retatrutide design. The human trial literature describes retatrutide as a glucagon receptor agonist in addition to GIP and GLP-1 receptor activity 2, 6.
The honest limit: receptor activity helps explain why retatrutide is being studied, but mechanism alone does not prove long-term benefit or safety for an individual person. Clinical outcomes and adverse events still have to be judged from human trial data 1, 4, 12.
Evidence
Evidence grade: A. The assigned grade is based on the retrieved PubMed set, which includes multiple human randomized controlled trials for retatrutide or LY3437943 1, 2, 3, 4, 5, 6, 7.
A — two or more human randomised controlled trials. B — one human randomised trial, or two or more human clinical trials. C — human research exists, none of it randomised. D — animal or in-vitro research only; no human studies indexed. E — no trial evidence indexed in PubMed. The grade describes the quantity and design of published evidence, not whether the substance works, and not whether it is safe.
What the grade means and does not mean
A grade A evidence label means the evidence base includes at least 2 human randomized controlled trials. It does not mean retatrutide is the right choice for a patient, does not remove safety concerns, and does not replace a clinician’s review.
The retrieved studies include phase 1b, phase 2, phase 2a, and phase 3 randomized trials. They studied retatrutide in obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, body composition, appetite and eating behavior, and cardiometabolic biomarkers 1, 2, 3, 4, 5, 7, 8.
Reviews and network meta-analyses have also evaluated GLP-1 receptor agonists and polyagonists, including retatrutide, for weight and metabolic outcomes. These analyses are useful for context, but they should not be read as direct head-to-head proof for one patient 9, 10, 11.
What studies exist
| Year | Design | Study | Journal | Record |
|---|---|---|---|---|
| 2023 | Randomised controlled trial | Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial | The New England journal of medicine | PMID 37366315 |
| 2023 | Randomised controlled trial | Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial c | Lancet (London, England) | PMID 37385280 |
| 2024 | Randomised controlled trial | Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial | Nature medicine | PMID 38858523 |
| 2026 | Randomised controlled trial | Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T | Lancet (London, England) | PMID 42250575 |
| 2025 | Randomised controlled trial | Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial | The lancet. Diabetes & endocrinology | PMID 40609566 |
| 2022 | Randomised controlled trial | LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple- | Lancet (London, England) | PMID 36354040 |
| 2025 | Randomised controlled trial | Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study | Diabetes, obesity & metabolism | PMID 40916752 |
| 2025 | Clinical trial | Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids | Diabetes, obesity & metabolism | PMID 40726454 |
| 2025 | Review / secondary | Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA | Obesity (Silver Spring, Md.) | PMID 40685589 |
| 2025 | Review / secondary | Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials | Journal of basic and clinical physiology and pharmacology | PMID 40728138 |
| 2025 | Review / secondary | Retatrutide-A Game Changer in Obesity Pharmacotherapy | Biomolecules | PMID 40563436 |
| 2026 | Primary study | Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials | Diabetes, obesity & metabolism | PMID 41090431 |
| Registration | Phase | Status | Enrolment | Title |
|---|---|---|---|---|
| NCT06808802 | PHASE1 | COMPLETED | 30 | To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants |
| NCT06354660 | PHASE3 | COMPLETED | 537 | Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) |
| NCT05611957 | PHASE1 | COMPLETED | 29 | A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function |
| NCT06003465 | PHASE1 | COMPLETED | 57 | A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices |
| NCT06297603 | PHASE3 | ACTIVE_NOT_RECRUITING | 320 | Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or |
| NCT04143802 | PHASE1 | COMPLETED | 72 | A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM) |
| NCT06982859 | PHASE1 | ACTIVE_NOT_RECRUITING | 95 | A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus |
| NCT07232719 | PHASE3 | ACTIVE_NOT_RECRUITING | 250 | A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight |
This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-02.
Reported dosing ranges
Studied doses are not instructions. The retrieved PubMed records confirm that retatrutide and LY3437943 dosing was studied in randomized trials, including a multiple-ascending-dose phase 1b trial, but the citation records supplied here do not provide a complete patient dosing schedule 6.
Because dose selection depends on trial design, eligibility rules, monitoring, adverse-event management, and study endpoints, trial dosing should not be copied for personal use. A clinician uses a different process than a research protocol.
| Study source | Population studied | Dose information available from the retrieved record | How to interpret it |
|---|---|---|---|
| Urva et al., phase 1b multiple-ascending-dose trial 6 | People with type 2 diabetes | The retrieved record states that multiple ascending doses were studied; exact numeric ranges are not provided in the supplied citation record. | This confirms dose-ranging research, not a patient-use protocol. |
| Jastreboff et al., phase 2 obesity trial 1 | Adults with obesity | The retrieved record identifies a phase 2 trial but does not provide full dose ranges in the supplied citation record. | Study dosing cannot be translated into self-directed dosing. |
| Rosenstock et al., phase 2 type 2 diabetes trial 2 | People with type 2 diabetes | The retrieved record identifies a randomized placebo- and active-controlled trial but does not provide full dose ranges in the supplied citation record. | A trial regimen is not personal dosing advice. |
| Sanyal et al., phase 2a MASLD trial 3 | People with metabolic dysfunction-associated steatotic liver disease | The retrieved record identifies a randomized phase 2a trial but does not provide full dose ranges in the supplied citation record. | Dosing must be interpreted with the trial’s inclusion rules and monitoring. |
| Bajaj et al., TRANSCEND-T2D-1 phase 3 trial 4 | People with type 2 diabetes and inadequate glycemic control with diet and exercise | The retrieved record identifies a phase 3 randomized trial but does not provide full dose ranges in the supplied citation record. | Phase 3 study design is not a dosing guide for the public. |
Legal status
| Date | Action | What it means | Source | Evidence |
|---|---|---|---|---|
| 2026-09-02 | Retatrutide is an investigational drug in active clinical trials (verified 2026-09-02) | Not approved and not compoundable. Material sold online as retatrutide is outside the regulated supply chain. | ClinicalTrials.gov | FDA / Federal Register |
This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-02. See the full legal-status tracker for every compound we follow.
Safety
Safety data exist in trials, but the details matter. The retrieved record set includes trials that evaluated efficacy and safety, including phase 2 and phase 3 studies in type 2 diabetes and phase 2 studies in obesity and metabolic liver disease 1, 2, 3, 4.
The supplied citation records do not provide enough detail to list exact adverse-event rates, specific contraindications, or a complete monitoring plan. That is not the same as saying there are no risks; it means this page should not invent safety details that are not in the retrieved evidence.
Gastrointestinal side effects in incretin trials
Retatrutide is studied within the incretin and GLP-1-based medication family, and the retrieved trials include safety evaluation as part of their design 2, 4, 9. The supplied records do not give enough extractable detail to name or rank specific gastrointestinal adverse events for retatrutide.
Heart rate and cardiometabolic safety signals
The retrieved literature includes cardiometabolic endpoints and biomarkers, including serum lipid-related work involving ANGPTL3/8, as well as broader type 2 diabetes and body-composition studies 5, 8. Biomarker changes are not the same as proof of long-term cardiovascular safety for a patient.
Why trial monitoring is different from self-directed use
A clinical trial has screening rules, study visits, adverse-event tracking, and stopping rules. Self-directed use does not recreate that structure, so trial results should not be treated as a do-it-yourself plan 1, 4, 12.
A separate safety issue is supply quality. Material sold online as “research use only” is not the same as medication dispensed by a licensed pharmacy after a clinician evaluation; identity, sterility, strength, and impurities may not be controlled in the same way.
Interactions
Interaction evidence is limited in the supplied record set. The retrieved PubMed citations include studies in people with type 2 diabetes and inadequate glycemic control, but they do not provide a complete interaction list for retatrutide 2, 4, 6.
Diabetes medicines and hypoglycemia context
Because retatrutide has been studied in type 2 diabetes, a clinician would need to review diabetes medications, glucose history, and hypoglycemia risk before any weight-loss or metabolic medication plan is considered 2, 4, 6.
Kidney impairment, liver disease, and other trial populations
The retrieved trial set includes metabolic liver disease research and type 2 diabetes research, including a phase 2a study in metabolic dysfunction-associated steatotic liver disease 3. These data do not replace individual review of kidney disease, liver disease, gallbladder history, pregnancy status, or other risks.
Drug absorption questions
The supplied PubMed records do not provide a completed, published interaction map for common oral drugs. When interaction studies are not fully published in the retrieved evidence set, that should be treated as an uncertainty, not reassurance.
How to obtain it legally
Start with a licensed clinician evaluation. A safe weight-loss medication process begins with medical history, current medications, diabetes status, pregnancy status, kidney and liver history, prior side effects, and goals. The clinician’s job is to decide whether prescription treatment is appropriate, and which option fits the person.
Chia does not offer retatrutide. We include it here because patients ask about it, and a clear answer helps people avoid confusing research terms with patient care.
For eligible patients seeking GLP-1-based care, Chia offers compounded semaglutide injection and compounded tirzepatide tablets or injections. Semaglutide plans currently start at $249/mo, tirzepatide tablet plans currently start at $249/mo, and tirzepatide injection plans currently start at $299/mo; product pages show current details.
| Chia option | Forms listed in Chia’s catalog | Plans currently start at | Notes |
|---|---|---|---|
| Semaglutide | Injection | $249/mo | Provider-guided dosing; microdosing plans available. |
| Tirzepatide | Tablets and injection | $249/mo for tablets; $299/mo for injection | Provider-guided dosing; microdosing plans available. |
| Weight + Energy | NAD+ injection plus choice of GLP-1 | $309/mo | A multi-treatment protocol listed in Chia’s catalog: Weight + Energy. |
| Weight + Muscle | Sermorelin injection plus choice of GLP-1 | $329/mo | A multi-treatment protocol listed in Chia’s catalog: Weight + Muscle. |
Chia care is 100% online: a short health questionnaire, then a licensed US provider reviews it and prescribes only when clinically appropriate. If prescribed, medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to the patient’s door; compounded drugs are not FDA-approved.
Patients can start with Chia’s eligibility quiz. Where it directly fits a patient’s workflow, Chia can also be reached by AI agents through DoctorMCP at mcp.chia.health for eligible treatments; a prescription still requires clinician review and is never guaranteed.
A research-chemical vendor is not a licensed clinician, and “research use only” material is not a prescription. For any weight-loss medication, the safety line is licensed care: a qualified prescriber, a legitimate pharmacy, clear labeling, and follow-up.
FAQ
Retatrutide, also called LY3437943, is a triple GIP, GLP-1, and glucagon receptor agonist studied in human trials for obesity, type 2 diabetes, metabolic liver disease, body composition, appetite, and related metabolic outcomes.
No. Ozempic is a brand name for semaglutide, a GLP-1 receptor agonist. Retatrutide is described in trials as a triple agonist at the GIP, GLP-1, and glucagon receptors.
Tirzepatide is known for GIP and GLP-1 receptor activity. Retatrutide is described in the supplied clinical literature as having GIP, GLP-1, and glucagon receptor activity. That receptor difference does not prove which medicine is best for an individual.
The retrieved human literature includes studies in obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, body composition, appetite and eating behavior, and lipid-related biomarkers.
The retrieved trials include safety evaluation, but the supplied citation records do not provide a complete adverse-event table or contraindication list. The practical risks include side effects, drug interactions, missed monitoring, and unsafe supply if a person uses non-prescription research material.
No. Trial dosing is part of a research protocol with screening, monitoring, and stopping rules. It is not personal dosing advice.
People may read about retatrutide through clinical-trial publications, media coverage, or online vendors. A research-chemical source is not the same as care from a licensed clinician and a licensed pharmacy.
No. Chia does not offer retatrutide. Chia does offer clinician-reviewed compounded semaglutide injection and compounded tirzepatide tablets or injections for eligible patients; compounded drugs are not FDA-approved.
References
- 1.PMID 37366315 [randomised controlled trial] Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. The New England journal of medicine. 2023.
- 2.PMID 37385280 [randomised controlled trial] Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet (London, England). 2023.
- 3.PMID 38858523 [randomised controlled trial] Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature medicine. 2024.
- 4.PMID 42250575 [randomised controlled trial] Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet (London, England). 2026.
- 5.PMID 40609566 [randomised controlled trial] Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The lancet. Diabetes & endocrinology. 2025.
- 6.PMID 36354040 [randomised controlled trial] Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet (London, England). 2022.
- 7.PMID 40916752 [randomised controlled trial] Kanu C, Boye KS, Poon JL, et al. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study. Diabetes, obesity & metabolism. 2025.
- 8.PMID 40726454 [clinical trial] Wen Y, Lemen D, Lin Y, et al. Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids. Diabetes, obesity & metabolism. 2025.
- 9.PMID 39305981 [review/secondary] Xie Z, Zheng G, Liang Z, et al. Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials. Metabolism: clinical and experimental. 2024.
- 10.PMID 40489581 [review/secondary] Wang Y, Zhou Y, Wang Z, et al. Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis. The Journal of clinical endocrinology and metabolism. 2025.
- 11.PMID 42419792 [review/secondary] Nong K, Shi Q, Xie X, et al. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ (Clinical research ed.). 2026.
- 12.PMID 41090431 [primary study] Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, obesity & metabolism. 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
